Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis

Mustafa Al-Mubarak1,2, Ariadna Tibau1, Arnoud J. Templeton1, David W. Cescon1, Alberto Ocana3, Bostjan Seruga4, Eitan Amir1*

1 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and Department of Medicine, University of Toronto, Toronto, Canada, 2 Ministry of Higher Education, Riyadh, Saudi Arabia, 3 Medical Oncology Department and Translational Research Unit, Albacete University Hospital, Albacete, Spain, 4 Sector of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Abstract

**Background:** Hormone receptor positive breast cancer is characterized by the potential for disease recurrence many years after initial diagnosis. Endocrine therapy has been shown to reduce the risk of such recurrence, but the optimal duration of endocrine therapy remains unclear.

**Methods:** We conducted a systematic review and meta-analysis to quantify the benefits and harms of extended adjuvant tamoxifen (>5 years of therapy) compared with adjuvant tamoxifen (5 years of therapy). Odds ratios (ORs) and 95% confidence intervals (CIs) were computed for disease recurrence, death and adverse events. Subgroup analyses by timing of recurrence and baseline lymph node and menopause status were carried.

**Results:** Five trials comprising 21,554 patients were included. Extended adjuvant tamoxifen was not associated with a significant reduction in the risk of recurrence (OR:0.89, 95% CI 0.76–1.05, p = 0.17). There was no association between extended adjuvant tamoxifen and all-cause death (OR:0.99, 95% CI 0.84–1.16, p = 0.88). There was an apparent reduction in risk of recurrence occurring after completion of extended adjuvant tamoxifen with little evidence of effect during therapy, however, this difference was not significant (p for difference 0.10). Subgroup analysis suggested that a greater effect size among lymph node positive patients compared with those who are lymph node negative (NNT: 25 vs. 49). There was no apparent difference in the effect between pre- and post-menopausal patients. Endometrial carcinoma was substantially more frequent with extended adjuvant tamoxifen (OR:2.06, 95% CI 1.65–2.58, p<0.001, number needed to harm:89).

**Conclusion:** In unselected patients, extended adjuvant tamoxifen is not associated with a significant reduction in recurrence, or a reduction in all-cause death. Patients with lymph node positive breast cancer may derive some benefit. Reduction in the risk of recurrence appears to occur only after completion of extended adjuvant therapy.

Introduction

Early hormone receptor expressing breast cancers are characterized by the propensity for late recurrence with approximately 50% of recurrences and deaths occurring 10 years or more after completion of 5 years of adjuvant endocrine therapy [1]. Methods for reducing late recurrences such as extended adjuvant hormone therapy are therefore of interest.

Both tamoxifen and aromatase inhibitors (AI) have been studied in the extended adjuvant setting. The use of AI after 5 years of adjuvant tamoxifen has shown a reduction in the risk of breast cancer recurrence in three studies [2–4]. In the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.17 study; treatment with 5 years of letrozole after 4.5–6 years of tamoxifen was associated with improvement in disease free survival (DFS) and distant DFS. However, despite improvements in DFS in both lymph node positive and negative patients, an improvement in overall survival was only seen in patients with node positive disease [2].

Studies of extended adjuvant tamoxifen (more than 5 years of therapy) compared with adjuvant tamoxifen (5 years or less of therapy) have shown mixed results. Two studies, the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [5] and the Scottish adjuvant tamoxifen trial [6] demonstrated no benefit of extended adjuvant tamoxifen. Moreover, the NSABP B-14 study showed in its interim analysis a greater number of recurrence events in those patients treated with extended adjuvant tamoxifen. A number of other studies have shown a reduction in breast cancer recurrence, including the recent results of the aTTom (Adjuvant Tamoxifen–To Offer More?) [7] and ATLAS (Adjuvant Tamoxifen: Longer Against Shorter) trials [8], as well as the combined analysis of the Eastern Cooperative Oncology Group (ECOG) E4181 and E5181 trials [9]; and a French trial.

---

**Citation:** Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, et al. (2014) Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis. PLoS ONE 9(2): e88238. doi:10.1371/journal.pone.0088238

**Editor:** Todd W. Miller, Dartmouth, United States of America

**Received** September 17, 2013; **Accepted** January 9, 2014; **Published** February 20, 2014

**Copyright:** © 2014 Al-Mubarak et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The authors have no support or funding to report.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: eitan.amir@uhn.ca
which compared 2 or 3 years of adjuvant tamoxifen with long term therapy.

In view of the variability in the results of trials of extended adjuvant tamoxifen, the true benefit of this treatment strategy is unknown. Furthermore, it is unclear if certain subgroups experience differential benefit from extended adjuvant tamoxifen. Here, we report a meta-analysis of randomized trials of extended adjuvant tamoxifen. The objectives were to assess the relative and absolute differences in efficacy and toxicity of extended adjuvant tamoxifen compared with adjuvant tamoxifen. We hypothesized that benefit of extended therapy may be limited to patients with lymph node positive disease, as has been observed with AIs.

Materials and Methods

Search Strategy

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [11]. Eligible trials were identified using a computerized search of the following databases: MEDLINE (host: PubMed); EMBASE (host: OVID), 1980–2013 week 20; American Society of Clinical Oncology Annual Meetings, 2005–2013; European Society of Medical Oncology/European Cancer Organization Meetings, 2005–2013; San Antonio Breast Cancer Symposium Annual Meetings, 2005–2012 and the Cochrane Central Register of Controlled Trials from January 1980 to April 2013. The search was restricted to English language articles. The terms “adjuvant,” “and “tamoxifen” and “breast cancer” and similar terms were cross-searched by using the following search algorithm: ((tamoxifen) AND (adjuvant) AND/Breast neoplasm MeSH OR (breast OR mammary) AND (carcinoma OR malignan* OR neoplasm OR tumor))) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trial [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial”) [tw] OR sing# [tw] OR doubl# [tw] OR treb# [tw] OR tripl# [tw] AND (ask# [tw] OR blind# [tw]) OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospective* [tw] OR volunteer* [tw] NOT (animals [mh] NOT humans [mh])). Included studies were randomized clinical trials that compared short duration of adjuvant tamoxifen therapy (defined as five years, adjuvant tamoxifen henceforth) to longer adjuvant tamoxifen therapy (defined as more than 5 years, extended adjuvant tamoxifen henceforth) as treatment in women with early breast cancer. Reference lists of eligible studies were also consulted for other relevant articles or abstracts. Both data from published articles and abstracts presented at annual meetings were included in a meta-analysis. The study was not registered and a protocol of the study was not published online.

Data Extraction

Data on efficacy, safety and tolerability were collected. Efficacy outcomes included risk of recurrence (including contralateral breast cancer), risk of distant recurrence, death without recurrence and death from any cause. Safety and tolerability data included pre-specified adverse events and discontinuation of treatment (defined as failure to continue allocated therapy for duration of trial). The following adverse events were pre-specified in this analysis: cardiac (including myocardial infarction, angina and congestive cardiac failure), venous thromboembolism, endometrial carcinoma and other non-breast malignancies. Events of interest were extracted from the primary publications and from any associated online appendices by two authors (MA-M and EA) using a standardized data extraction form. Discrepancies were resolved by consensus.

Data Synthesis

The analysis was performed in multiple cohorts. Initial analyses were carried out for data from all randomized patients. Subsequent analyses excluded data from patients whose tumors were shown not to express the estrogen receptor (ER, i.e. a combination of patients who were ER-positive or ER-unknown). A sensitivity analysis was conducted to assess the effect of patients with ER-unknown tumors on estimates of interest. Subgroup analyses were also planned to assess the events of interest in subgroups frequently reported by individual studies. These included assessment by time of recurrence (during extended adjuvant therapy or beyond), lymph node status (negative versus positive) and by menopausal status (premenopausal versus postmenopausal at the time of enrolment).

Statistical Analysis

Data on relative event rates of interest were expressed as odds ratios (OR) and their respective 95% confidence intervals (CI) for the experimental arms compared with the control groups. Data were then included in a meta-analysis using RevMan 5.1 software (Cochrane Collaboration, Copenhagen, Denmark). Pooled estimates of OR were computed using the Mantel-Haenszel OR method [12,13]. The random effect model was used if the p-value for Cochran’s Q was <0.1 or if the I² index was >50% [13]. Otherwise, the fixed effect model was utilized. Differences between the subgroups were assessed using methods described by Deeks et al [14]. Absolute risks of event of interest were calculated as the number of events per person after 10 years of follow-up where available. The difference in absolute risk between extended adjuvant and adjuvant tamoxifen was also presented as the number needed to treat (NNT) or the number needed to harm (NNH). These estimates quantify the number of patients that would need to be treated with extended adjuvant tamoxifen to cause a beneficial or detrimental event of interest in one patient who would not otherwise have experienced that event. All statistical tests were two-sided, and statistical significance was defined as p<0.05. No corrections were made for multiple testing. Sensitivity analyses were also conducted for trials with heterogeneous eligibility criteria.

Results

The search identified a total of 2283 citations. After applying our eligibility criteria, 1285 review articles and commentaries and 367 articles of trials conducted in metastatic breast cancer were initially excluded. Of the remaining 630 articles, 621 were excluded as they investigated aromatase inhibitors or chemotherapy in either the control or experimental arms. Three duplicate articles were also excluded as was one study [10] where the control arm was 2–3 years of tamoxifen rather than 5 years. Six citations [5–9,15] reporting results of five studies were therefore eligible for analysis and included two [7,15] recently reported results of the aTTom trial. A further commentary [16] presenting updated results of one randomized trial [9] was identified through a review of reference lists and was also included in the analysis (see figure 1). Characteristics of included studies are shown in Table 1. Four studies [5,6,8,9] (83%) provided data on disease recurrence for subgroups of patients with ER-positive primary breast cancer (i.e. after excluding ER-negative and ER-unknown cases if applicable); while in one study [7] only data on a combined group of ER-positive and ER-unknown were available. Three [6–8] of the five
included studies provided follow-up data to 10 years and were included in the assessment of absolute risks.

**Efficacy**

Among all randomized patients, extended adjuvant tamoxifen was not associated with a significant reduction in the odds of breast cancer recurrence (OR 0.89, 95% CI 0.76–1.05, p = 0.17, see figure 2).

Subgroup analysis using data from patients with ER-positive primary breast cancer (including one study which also included ER-unknown cases [7]) showed a numerically lower estimate, but did not differ significantly from the whole group (OR 0.85, 95% CI 0.72–1.00, p for difference = 0.66). Exclusion of one study [7] which was unable to differentiate ER-positive and ER-unknown patients failed to show a difference in risk of recurrence (OR 0.89, 95% CI 0.75–1.06, p for difference = 0.60).

Data on timing of recurrence were available from all eligible studies. Analysis showed that benefit from extended tamoxifen may occur beyond extended adjuvant therapy (OR 0.80, 95% CI 0.73–0.88) with no evidence of benefit during extended adjuvant therapy (OR 1.01, 95% CI 0.79–1.29). This difference approached, but did not meet statistical significance (subgroup difference p = 0.10, see figure 3). Data based on baseline lymph node status were available from all eligible studies. Analysis showed similar results with apparent benefit seen only among those with lymph node positive disease (OR 0.76, 95% CI 0.63–0.92) and not in those that were lymph node negative (OR 0.93, 95% CI 0.76–1.14, see figure 4). This difference, however, was not statistically significant (subgroup difference p = 0.16). At 10 years of follow-up, the absolute risk reduction was 2.1% in lymph node negative patients (NNT: 49) and 4.1% in lymph node positive patients (NNT: 25). Data on baseline menopause status were available from three studies [6,8,9] and among these, 822 women (13%) were documented to be pre-menopausal. There was no apparent effect of menopause status on breast cancer recurrence (OR for pre-menopause 0.80, 95% CI 0.57–1.12 compared with OR for post-menopause 0.86, 95% CI 0.64–1.14, subgroup difference p = 0.76).

Data on distant recurrence were available from three [5,8,9] of the five eligible studies. Compared with 5 years of tamoxifen, there was no difference in the odds of distant recurrence with extended adjuvant tamoxifen (OR 0.96, 95% CI 0.66–1.38, p = 0.81).
Similarly, there was no association between extended tamoxifen and death after breast cancer recurrence (OR 0.98, 95% CI 0.79–1.21, p = 0.82).

There was no apparent association between extended tamoxifen and all cause death (OR 0.99, 95% CI 0.84–1.16, p = 0.88, see figure 5A). There was significant heterogeneity among studies (Cochran’s Q p = 0.05 and $I^2$ index = 59%). The estimate was sensitive to the modeling method used to weight studies. Use of fixed effects modeling was associated with a statistically significant and lower OR ($p$ for difference = 0.32), likely as a result of substantially higher weighting for the ATLAS and aTTom trials (36.8% and 37.3% versus 45.7% and 48.2% respectively). Data on all-cause death in those known to have ER-positive disease were available from four studies [5,6,8,9]. Results were similar to those for patients with unselected ER status (OR 1.11, 95 CI 0.79–1.55, $p$ = 0.55). Again significant heterogeneity was seen (Cochran’s Q $p$ = 0.02 and $I^2$ index = 69%). Despite, a numerically higher number of deaths in the extended tamoxifen group, there was no association between extended tamoxifen and death without breast cancer recurrence (OR 1.02, 95% CI 0.94–1.11, $p$ = 0.67, see figure 5B).

Data on absolute risk difference and NNT at 10 years of follow-up are shown in Table 2.

### Safety and Tolerability

Extended adjuvant tamoxifen was associated with a significant increase in endometrial carcinoma (OR 2.06, 95% CI 1.65–2.58, $p$ < 0.001). At 10 years of follow-up, the absolute risk increased from 1.1% in the adjuvant tamoxifen group to 2.2% in the extended adjuvant group (NNH 89). Among the small cohort of patients who developed endometrial carcinoma (n = 344), receipt of extended adjuvant tamoxifen was associated with a non-significant increase in the risk of endometrial carcinoma (OR 0.93, 95% CI 0.46, 1.92, $p$ = 0.85).

### Table 1. Characteristics of Included Studies.

| Trial                        | Median Follow-up (years)* | Node positive (%) | Duration of therapy in control arm (years) | Duration of therapy in experimental arm (years) | Sample Size | OR for Recurrence 95% CI | P       |
|------------------------------|---------------------------|-------------------|-------------------------------------------|-----------------------------------------------|-------------|---------------------------|---------|
| **All Patients**             |                           |                   |                                           |                                               |             |                           |         |
| ATLAS [8]                    | 7.6*                      | 40                | 5                                         | 10                                            | 12894       | 0.85                      | 0.76, 0.95 | 0.006 |
| aTTom [7,15]                 | ~9**                     | 31                | 5                                         | 10                                            | 6953        | 0.84                      | 0.74, 0.95 | 0.006 |
| ECOG E4181/E5181 [9,16]      | 9.6                       | 100               | 5                                         | indefinite                                    | 193         | 0.45                      | 0.23, 0.89 | 0.02  |
| NSABP B14 [5]               | 7                         | 0                 | 5                                         | 10                                            | 1172        | 1.18                      | 0.80, 1.72 | 0.41  |
| Scottish Trial [6]           | 10                        | 23                | 5                                         | indefinite                                    | 342         | 1.36                      | 0.83, 2.22 | 0.22  |
| **ER-positive**              |                           |                   |                                           |                                               |             |                           |         |
| ATLAS [8]                    | 7.6*                      | 42                | 5                                         | 10                                            | 6846        | 0.84                      | 0.74, 0.94 | 0.003 |
| aTTom [7,15]                 | ~9**                     | NR                | 5                                         | 10                                            | 6953        | 0.84                      | 0.74, 0.95 | 0.006 |
| ECOG E4181/E5181 [9,16]      | 9.6                       | 100               | 5                                         | indefinite                                    | 140²        | 0.33                      | 0.15, 0.70 | 0.004 |
| NSABP B14 [5]               | 7                         | 0                 | 5                                         | 10                                            | 1172        | 1.18                      | 0.80, 1.72 | 0.41  |
| Scottish Trial [6]           | 10                        | NR                | 5                                         | indefinite                                    | 132³        | 0.93                      | 0.46, 1.92 | 0.85  |

Table 1. Characteristics of Included Studies.

| Study          | Weight | Odds Ratio [95% CI] |
|----------------|--------|---------------------|
| ATLAS         | 36.7%  | 0.85 [0.76, 0.95]   |
| aTTom         | 36.0%  | 0.84 [0.74, 0.95]   |
| ECOG E4181/E5181 | 5.1%    | 0.45 [0.23, 0.89]   |
| NSABP B14     | 13.1%  | 1.18 [0.80, 1.72]   |
| Scottish Trial | 9.0%   | 1.36 [0.83, 2.22]   |
| **Total**     | 100.0% | 0.89 [0.76, 1.05]   |

Heterogeneity: $P = 0.05$; $I^2$ = 58%

Test for overall effect: $P = 0.17$

Figure 2. Forest plots of odds ratios for breast cancer recurrence for patients treated with extended adjuvant tamoxifen (>5 years) versus adjuvant tamoxifen (5 years) based on primary analysis of individual trials. Odds ratios for each trial are represented by the squares, the size of the square represents the weight of the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval. The diamonds represent the estimated pooled effect (labeled total).

DOI: 10.1371/journal.pone.0088238.g002
significant lower odds of death from endometrial carcinoma (OR 0.71, 95% CI 0.42–1.20, p = 0.20).

Data on non-breast, non-endometrial cancers were available from four [5,6,8,9] of the five eligible studies. There was no association between extended adjuvant tamoxifen and these cancers (OR 0.91, 95% CI 0.80–1.03, p = 0.14). At 10 years of follow-up, the absolute difference in risk was 0.4% and the NNH was 203.

Extended adjuvant tamoxifen was not associated with a significant reduction in death from cardiovascular disease (OR 0.89, 95% CI 0.73–1.09, p = 0.25). At 10 years of follow-up, the absolute risk changed from 3.2% in the adjuvant tamoxifen group to 2.8% in the extended adjuvant tamoxifen group. The NNT to prevent one cardiovascular death was 236.

Data on venous thromboembolism were only reported in two [8,9] of the six eligible studies. One study reported the incidence and mortality from pulmonary embolism while the other reported the incidence of deep venous thrombosis. Consequently, these data were not pooled in a meta-analysis.

As only one study was placebo controlled, relative risks of treatment discontinuation could not be assessed. Among those receiving extended adjuvant tamoxifen, treatment was discontinued in 38% of patients (95% CI 37–39%).

**Discussion**

Despite a predisposition for late recurrence, long-term endocrine therapy for hormone receptor positive breast cancer is not routinely recommended for all patients [17,18]. Multiple studies have assessed the hypothesis that extending the duration of endocrine therapy will result in a reduction of breast cancer recurrences. Data are currently available from studies which enrolled patients treated initially with tamoxifen alone and randomized these either to ongoing tamoxifen or AI. Results of these studies have been mixed leading to uncertainty regarding the benefit of extended adjuvant endocrine therapy.

Here we report on a published data meta-analysis of trials of 5 years versus longer duration (more than five years) of tamoxifen. Results show that in unselected patients, extended adjuvant tamoxifen was not associated with a significant reduction in the odds of breast cancer recurrence or a reduction in all cause death. There was significant statistical heterogeneity among included studies and this necessitated the use of random effects modelling. Use of fixed effect modelling or of individual patient data would have led to higher weighting of larger studies such as ATLAS and aTTom and may have led to statistically significant reductions in breast cancer recurrence or all cause death. Such methods were, however, not feasible in the current analysis.

Of interest, among studies reporting a negative association between extended adjuvant tamoxifen and breast cancer recurrence, eligible patients were either all node negative [5] or predominantly (77%) lymph node negative [6]. The remaining three studies [7–9], all of which included a greater proportion of lymph node positive patients, individually reported benefit from extended adjuvant tamoxifen. Lymph node involvement appears to be prognostic for late relapse [19,20]. Furthermore, in women...
receiving extended adjuvant therapy with AI, lymph node positive disease was also associated with translation of improvements in DFS into improvements in OS [2]. This observation was not seen in lymph node negative patients. Results from the current analysis suggest a trend for more benefit in women with node positive disease.

The association of extended adjuvant tamoxifen and breast cancer recurrence appeared to be influenced by the time of recurrence. Extended adjuvant tamoxifen appeared to have little to no effect on breast cancer recurrence during therapy (years 5 to 9 after initial diagnosis), with a modest reduction in recurrence seen after completion of extended adjuvant therapy (beyond year 10). This finding may be explained by the ongoing effect of the initial (adjuvant) period of tamoxifen therapy. Data from studies of extended adjuvant AI show that despite this well recognized hangover effect [1], patients who discontinue adjuvant tamoxifen as much as 5 years earlier may benefit from extended adjuvant endocrine therapy [21]. These data are of clinical relevance to post-menopausal women treated with tamoxifen alone for the first 5 years. In contrast to our data, a meta-analysis of extended adjuvant AI [22] (after 5 years of adjuvant tamoxifen) showed statistically significant and higher magnitude of reduction of breast cancer recurrence. Furthermore, extended adjuvant therapy with AI was associated with benefit even during the period of treatment [2]. In the absence of comparative data of extended tamoxifen versus extended AI, the earlier benefit seen from AI suggests that in post-menopausal women, provision of extended adjuvant AI may be more favourable than tamoxifen. Our subgroup analysis supports the potential benefit of extended adjuvant tamoxifen for selected pre-menopausal women. However, pre-menopausal women comprised only a small proportion of all randomized patients (13%) and therefore, there is some uncertainty regarding the potential benefit of extended adjuvant tamoxifen in this group. Extended tamoxifen may also be suitable for women who are intolerant of extended adjuvant AI and those living in areas where AI are prohibitively expensive. The utility of extended adjuvant endocrine therapy in patients who have received either upfront adjuvant AI or a sequencing strategy remains unknown and will be answered by a number of ongoing studies [23–25].

Compliance with tamoxifen was suboptimal with 38% of patients discontinuing study drug before completion of 5 years of extended therapy. This rate is slightly higher than that seen in the adjuvant trials where between 20 and 25% of patients discontinued tamoxifen within the first 5 years of treatment [1,26]. However, this rate is similar to the rate of discontinuation of adjuvant tamoxifen observed in population-based studies [27]. The rate of discontinuation of extended adjuvant AI in the NCIC CTG MA.17 trial was lower, where ~20% of patients discontinued the extended adjuvant AI and in women age 70 years or older the rate of discontinuation was similar to the placebo [28]. This low level of compliance may underestimate the true efficacy of extended adjuvant therapy.

The estimates of benefit of extended adjuvant tamoxifen could also be affected by the inclusion of patients with ER-negative or ER-unknown cancers. While it was possible to perform a sensitivity analysis after exclusion of patients with ER-negative from all studies and ER-unknown from the ATLAS and the Scottish trial, it was not possible to exclude patients with ER-unknown from the aTTom trial because such data were not
reported. The percentage of ER-unknown after exclusion of ER-negative from all studies and ER-unknown from the ATLAS and the Scottish trial was 27%. Furthermore, it was estimated that only 80% of ER-unknown patients in the aTTom trial were ER-positive. The effect of inclusion of these patients is difficult to estimate but may underestimate the efficacy of extended adjuvant tamoxifen.

The effects of extended adjuvant tamoxifen on non-breast cancer deaths are of interest, especially with cardiovascular disease now being the predominant cause of death in older women with breast cancer [29,30]. Overall, there was no significant difference in the odds of death without recurrence between extended adjuvant tamoxifen and control groups; however, there was a non-significant numerical reduction in the odds of cardiovascular death with extended adjuvant tamoxifen. In postmenopausal women, tamoxifen can have beneficial effects on cholesterol and other serum lipids such as low-density lipoproteins [31,32]. However, data also show an association between tamoxifen and unfavorable effects on serum triglycerides [33,34]. This balance between improvements in serum cholesterol and detrimental effect reported. The percentage of ER-unknown after exclusion of ER-negative from all studies and ER-unknown from the ATLAS and the Scottish trial was 27%. Furthermore, it was estimated that only 80% of ER-unknown patients in the aTTom trial were ER-positive. The effect of inclusion of these patients is difficult to estimate but may underestimate the efficacy of extended adjuvant tamoxifen.

The effects of extended adjuvant tamoxifen on non-breast cancer deaths are of interest, especially with cardiovascular disease now being the predominant cause of death in older women with breast cancer [29,30]. Overall, there was no significant difference in the odds of death without recurrence between extended adjuvant tamoxifen and control groups; however, there was a non-significant numerical reduction in the odds of cardiovascular death with extended adjuvant tamoxifen. In postmenopausal women, tamoxifen can have beneficial effects on cholesterol and other serum lipids such as low-density lipoproteins [31,32]. However, data also show an association between tamoxifen and unfavorable effects on serum triglycerides [33,34]. This balance between improvements in serum cholesterol and detrimental effect recorded.

**Table 2.** Unweighted absolute risks and number needed to treat (NNT) for events of interest after 10 years of follow-up.

| Event of interest               | Number of included studies | Absolute risk in extended adjuvant tamoxifen group | Absolute risk in adjuvant tamoxifen group | Absolute risk difference | NNT* |
|--------------------------------|---------------------------|---------------------------------------------------|-----------------------------------------|--------------------------|------|
| Any recurrence (all patients)  | 3 [6,8,15]                | 1.27%                                             | 1.45%                                   | 0.18%                    | 57   |
| Any recurrence (excluding ER-negative) | 3 [6,8,15]               | 1.75%                                             | 2.02%                                   | 0.27%                    | 38   |
| Distant recurrence             | 1 [8]                     | 15.0%                                             | 16.2%                                   | 1.3%                     | 79   |
| Death after recurrence         | 3 [6,8,15]                | 7.7%                                              | 8.7%                                    | 1.0%                     | 101  |
| Death without recurrence       | 3 [6,8,15]                | 11.9%                                             | 11.8%                                   | -0.008%                  | -1281|
| All cause death                | 3 [6,8,15]                | 15.4%                                             | 16.7%                                   | 1.3%                     | 79   |

95% CI, 95% confidence intervals. ER, estrogen receptor.

*Negative value suggests more events in extended adjuvant group (i.e. net harm).

[doi:10.1371/journal.pone.0088238.t002]
on serum triglycerides may explain the non-significant effects on cardiovascular death in our analysis.

As expected, extended adjuvant tamoxifen was associated with an increase in the incidence of endometrial carcinoma. The proportion of patients with prior hysterectomy in included studies was not uniformly reported, therefore, the estimations of risk for this adverse event in women with an intact uterus are subject to some uncertainty. Interestingly, in our analysis it appeared that endometrial carcinoma which developed in women on extended tamoxifen was associated with lower odds of death than that of those who only received adjuvant tamoxifen. However, the number of analyzable events was small leading to some uncertainty regarding this estimate. The reasons for this observation are not clear, and reports describing the prognosis of tamoxifen-induced endometrial carcinoma have been quite varied [35–41]. This finding may be explained by endometrial carcinoma in the extended tamoxifen arm having more a favourable prognosis and consequently a lower risk of death. Alternatively, as included studies were predominantly open-label, it is possible that a more rigorous follow-up and investigation of atypical vaginal bleeding in women receiving tamoxifen compared to controls may have led to earlier detection of endometrial carcinoma.

This study has several limitations. First, this is a meta-analysis of the literature rather than of individual patient data and is based on reports of trials with different durations of follow-up. We were therefore unable to report actuarial rates of recurrence or toxicity. Second, collection of data for the purpose of this meta-analysis was therefore unable to report actuarial rates of recurrence or toxicity. We were therefore unable to report actuarial rates of recurrence or toxicity. Alternatively, as included studies were predominantly open-label, it is possible that a more rigorous follow-up and investigation of atypical vaginal bleeding in women receiving tamoxifen compared to controls may have led to earlier detection of endometrial carcinoma.

In conclusion, in unselected patients, extended adjuvant tamoxifen is not associated with a significant reduction in recurrence or a reduction in all-cause death. Patients with lymph node positive breast cancer may derive some reduction in recurrence although the long-term effects of this on all-cause death remain unclear. Individual patient meta-analysis should address whether improvements in the risk of recurrence translate into survival improvements in patients with node positive disease.

Supporting Information

Checklist S1 PRISMA Checklist.

(DOC)

Author Contributions

Conceived and designed the experiments: MA-M EA. Performed the experiments: MA-M EA. Analyzed the data: MA-M EA AT DWC AO BS. Contributed reagents/materials/analysis tools: EA. Wrote the paper: MA-M EA AT DWC AO BS.

References

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771–781.
2. Goss PE, Ingle JN, Martinot S, Robert NJ, Moss HB, et al. (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst 97: 1262–1271.
3. Jakes R, Greil R, Grant M, Schmid M, Kwasyw A, et al. (2007) Extended adjuvant therapy with aromatase inhibitors among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99: 1845–1853.
4. Mamounas EP, Jonng JH, Wickerham DL, Smith RE, Ganz PA, et al. (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-23 trial. J Clin Oncol 26: 1965–1971.
5. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93: 684–690.
6. Stewart HJ, Prescott RJ, Forrest AP (2001) Scottish adjuvant tamoxifen trial: a randomised study updated to 13 years. J Natl Cancer Inst 93: 456–462.
7. Gray RG, Rea D, Handley D, Bowden SJ, Perry P (2013) aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol 31: suppl; abstr 5.
8. Davies C, Pan H, Godwin J, Gray R, Arriagada R, et al. (2012) Long-term effects of continuing tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 4: 6190–6190.
9. Tormey DC, Gray R, Falkon HC (1996) Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 98: 1828–1833.
10. Delozier T, Spielmann M, Mace-Lesec'h J, Janvier M, Hill C, et al. (2000) Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol 18: 3507–3512.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(10): e1000097.
12. Swets MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23: 1351–1375.
13. Higgins JPT, Deeks JJ, Altman DG (2011) Meta-analysis of rare events, in Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). The Cochrane Collaboration. http://www.cochrane-handbook.org.
14. Deeks JJ [2001] Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 325: 157–162.
15. Rea DW, Gray RG, Bowden SJ, Handle K, Earl HM (2015) Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer. The European Cancer Congress, 2013 (2013) Scientific Programme – Published Papers. European Journal of Cancer 49, Supplement 2: S286–S449, Abstract 1860.
16. Bryant J, Fisher B, Dignam J (2001) Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 30: 56–61.
17. Burstein HJ, Prestrud MA, Seidenfeld J, Anderson H, Buchholz TA, et al. (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28: 3704–3706.
18. Goldhirsch A, Winer EP, Coates AS, Gelbert RD, Piccart-Gebhart M, et al. (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Galien International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24: 2206–2223.
19. Sapin F, Torreyn DC, Gray R, (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738–2746.
20. Krennke IH, Olivoto IA, Speers C, Norris B, Chia SK, et al. (2007) Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18: 43–51.
21. Goss PE, Ingle JN, Pater JL, Martinot S, Robert NJ, et al. (2008) Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26: 1948–1955.
22. Goss PE, Jakes R, Markopoulou G, Dowsett M, Peto R (2009) Aromatase Inhibitors (AIs) versus not placebo/observation as late extended adjuvant therapy for postmenopausal women with early stage breast cancer (BC): overview of randomized trials of AIs after ~3 years of tamoxifen. San Antonio Breast Cancer Symposium San Antonio, TX (, 2009). Cancer Res 2009;69(24 Suppl): Abstract nr 4081.
23. ClinicalTrials.gov website. Available : http://clinicaltrials.gov/ct2/show/ NCT010559140. Accessed 2014 January 14.
24. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/ NCT00382070. Accessed 2014 January 14.

25. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/ NCT00295620. Accessed 2014 January 14.

26. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131–2139.

27. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, et al. (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28: 4120–4128.

28. Muss HB, Tu D, Ingle JN, Martin M, Robert NJ, et al. (2008) Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen. NCIC CTG intergroup trial MA.17. J Clin Oncol 26: 1956–1964.

29. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Maskey JR (2007) Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50: 1435–1441.

30. Patnak JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13.

31. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, et al. (1988) Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12: 307–310.

32. Dewar JA, Horobin JM, Preece PE, Tavendale R, Twinn-st-Pedoe H, et al. (1992) Long term effects of tamoxifen on blood lipid values in breast cancer. Br J Cancer 305: 225–228.

33. Hozumi Y, Kawano M, Saito T, Miyata M (1998) Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 83: 1633–1635.

34. Liu CL, Yang TL (2003) Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 79: 11–16.

35. Barakat RR, Wong G, Currim JP, Vlannis V, Hoskins VJ (1994) Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55: 164–168.

36. Bergman L, Beelen ML, Gallego MA, Bolhassa J, et al. (2006) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356: 881–887.

37. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527–537.

38. Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, et al. (2012) Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 14.

39. Jordan VC, Assikis VJ (1995) Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1: 467–472.

40. Migotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, et al. (1998) Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer 76: 325–330.

41. Swerdlow AJ, Jones ME (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a pooled analysis of individual patient data from four breast cancer cohorts. J Natl Cancer Inst 97: 375–384.

42. Black WC, Haggstrom DA, Welch HG (2002) All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94: 167–173.

43. Lavaud WS, Day RO (2003) Adverse event reporting in clinical trials: room for improvement. Med J Aust 179: 426–428.

44. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474–1481.